In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sihuan Pharmaceutical grosses HK$5.75bn via its IPO

Executive Summary

Sihuan Pharmaceutical Holdings Group Ltd., China's largest cardio-cerebral vascular drugs producer, has grossed HK$5.75bn ($738mm) through the initial public offering of 1.25bn shares at HK$4.60 each on the Hong Kong Stock Exchange. The shares sold at the top of the range, which began at HK3.88, and the financing was more than 100 times oversubscribed.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies